NASDAQ:APLM Apollomics (APLM) Stock Price, News & Analysis $16.51 -1.33 (-7.46%) Closing price 03:58 PM EasternExtended Trading$16.60 +0.08 (+0.51%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Apollomics Stock (NASDAQ:APLM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Apollomics alerts:Sign Up Key Stats Today's Range$16.61▼$17.8750-Day Range$16.51▼$25.5452-Week Range$12.58▼$28.29Volume9,592 shsAverage Volume18,619 shsMarket Capitalization$48.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Apollomics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer, with an emphasis on targeted therapies and immuno-oncology. The company has operated in the United States and China. Its lead candidate, vebreltinib (APL-101), is an investigational, selective inhibitor of the MET protein being studied in cancers with alterations in the MET pathway, including certain lung cancers. Apollomics has also described additional investigational oncology candidates in its pipeline. Apollomics’ drug candidates are in development and are not approved medicines. The company was founded in 2015; its programs are intended to address cancers for which existing treatment options may be limited.AI Generated. May Contain Errors. Read More Apollomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreAPLM MarketRank™: 0.87581525356 of 5 starsApollomics scored higher than 18% of companies evaluated by MarketBeat, and ranked 806th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingApollomics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageApollomics has only been the subject of 1 research reports in the past 90 days.Read more about Apollomics' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.19% of the float of Apollomics has been sold short.Short Interest Ratio / Days to CoverApollomics has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apollomics has recently increased by 0.07%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApollomics does not currently pay a dividend.Dividend GrowthApollomics does not have a long track record of dividend growth. News and Social Media3.4 / 5News SentimentN/A News SentimentApollomics has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Apollomics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Apollomics to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Apollomics insiders have not sold or bought any company stock.Percentage Held by Institutions19.13% of the stock of Apollomics is held by institutions.Read more about Apollomics' insider trading history. Receive APLM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APLM Stock News HeadlinesApollomics Reports First-Half 2026 Financial ResultsNovember 9, 2026 | markets.businessinsider.comApollomics Inc - Ordinary Shares - Class AAugust 19, 2026 | money.usnews.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 17 at 1:00 AM | Behind the Markets (Ad)Apollomics IncAugust 18, 2026 | markets.ft.comApollomics Announces $10 Million Private Placement TransactionAugust 11, 2026 | globenewswire.comApollomics Inc. Class AAugust 10, 2026 | edition.cnn.comApollomics Inc. Class A Ordinary Shares (APLM)July 14, 2026 | nasdaq.comApollomics Regains Full Compliance with Nasdaq Listing RequirementsJuly 13, 2026 | markets.businessinsider.comSee More Headlines APLM Stock Analysis - Frequently Asked Questions How have APLM shares performed this year? Apollomics' stock was trading at $18.69 at the start of the year. Since then, APLM stock has decreased by 11.7% and is now trading at $16.51. How were Apollomics' earnings last quarter? Apollomics Inc. (NASDAQ:APLM) issued its quarterly earnings data on Friday, November, 6th. The company reported ($2.02) earnings per share (EPS) for the quarter. When did Apollomics' stock split? Apollomics's stock reverse split on Monday, November 25th 2024.The 1-100 reverse split was announced on Thursday, November 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Apollomics? Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/06/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 5 days ago, APLM's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:APLM CIK1944885 Webwww.apollomicsinc.com Phone(650) 209-4055Fax650-288-1674Employees15Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick RatioN/A Sales & Book Value Annual Sales$8.50 million Price / Sales5.65 Cash FlowN/A Price / Cash FlowN/A Book Value($2.89) per share Price / Book-5.71Miscellaneous Outstanding Shares2,910,000Free FloatN/AMarket Cap$48.04 million OptionableNot Optionable Beta1.57 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:APLM) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.